Back to results
US 10,500,252 B2Granted
Method of treating intracellular infection
AssigneeThe Walter and Eliza Hall Institute of Medical Research
InventorsMarc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
Claims24
A method of treating a persistent intracellular infection in which tumor necrosis factor (TNF) is produced, the method comprising administering to a subject in need thereof an effective amount of an Inhibitor of Apoptosis (IAP) antagonist
- wherein the intracellular infection is a viral infection caused by a virus selected from the group consisting of Human papillomaviruses, Herpes viruses, Human papovaviruses, adenoviruses, parvoviruses, human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-cell lymphotropic virus (HTLV), or
- wherein the intracellular infection is a bacterial infection caused by a bacteria selected from the group consisting of Salmonella spp., Ehrlichia spp., Mycobacteria spp., Spirochetes, Legionella spp Listeria spp., Rickettsia spp., Chlamydia spp., Mycoplasma spp., Coxiella spp., Yersinia spp., Francisella spp., Brucella spp., Neisseria spp, and Nocardia spp.;
- and
- wherein the IAP antagonist is a monovalent IAP antagonist, a bivalent IAP antagonist, a nonpeptidomimetic IAP antagonist, or an IAP antagonist that reduces expression of an IAP gene.
1 more element
Dependencies are inferred from the claim text.